Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.34 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9970276 | 0.80 | TSHR (0.42) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL8989873 | 0.80 | TSHR (0.42) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL9970576 | 0.80 | TSHR (0.42) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL13867763 | 0.79 | TSHR (0.37) | TSHRHSD17B10MGAMGAASI | |
| Hydrochloric Acid SCHEMBL5419950 | 0.78 | TSHR (0.40) | TSHRHSD17B10MGAMGAASI | |
| Hydrochloric Acid SCHEMBL9936423 | 0.78 | TSHR (0.40) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL28740616 | 0.77 | TSHR (0.39) | TSHRHSD17B10MGAMGAASI | |
| SCHEMBL1661431 | 0.75 | — | — | |
| SCHEMBL1144127 | 0.75 | — | — | |
| SCHEMBL4375047 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11071730-B2 | Substituted 6-azabenzimidazole compounds | GILEAD SCIENCES, INC. (US) | 2021-07-27 | — | — | US | disclosed |
| US-20200171020-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | GILEAD SCIENCES, INC. | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11071730-B2 | Substituted 6-azabenzimidazole compounds | CDK6, HIPK1, DCK | TSHR 4603/4885HSD17B10 1769/4885MGAM 4356/4885 |
| US-20200171020-A1 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS | CDK6, HIPK1, DCK | TSHR 4603/4885HSD17B10 1769/4885MGAM 4356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.